Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19) is under clinical development by ImmunityBio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19)’s likelihood of approval (LoA) and phase transition for Metastatic Pancreatic Cancer took place on 27 Dec 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19) overview

Cellular immunotherapy (haNK program, CST-103) is under development for the treatment of solid tumor, metastatic pancreatic cancer (second), triple negative breast cancer, colorectal cancer, squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma urothelial carcinoma, epithelial ovarian carcinoma and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered as an intravenous infusion. The therapy comprises of NK cells which are developed by using NK-92 cancer killing cell line platform.

It was also under development for the treatment of metastatic melanoma, hepatocellular carcinoma, merkel cell carcinoma, metastatic pancreatic cancer (first line), urothelial carcinoma and epithelial ovarian carcinoma, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, rhabdomyosarcoma, non-muscle invasive bladder cancer, Hodgkin lymphoma, gastroesophageal cancer, Ewing sarcoma and chordoma.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

Quick View Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19) LOA Data

Report Segments
  • Innovator
Drug Name
  • Cellular Immunotherapy 2 for Oncology and Coronavirus Disease 2019 (COVID-19)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.